Phase 2 KEYNOTE-057 cohort C: Pembrolizumab (pembro) with vibostolimab or favezelimab for patients (pts) with high-risk (HR) bacillus Calmette-Guérin (BCG)-unresponsive non–muscle-... von Shore, Neal D., Gupta, Shilpa, Kulkarni, Girish S., Necchi, Andrea, Dave, Hema Kishore, Kapadia, Ekta, Zhao, Qing, Kamat, Ashish M.

Volltext

Brentuximab vedotin and association with event-free survival (EFS) in children with newly diagnosed high-risk Hodgkin lymphoma (HL): A report from the Children's Oncology Group pha... von Castellino, Sharon M., Pei, Qinglin, Parsons, Susan K., Hodgson, David C., McCarten, Kathleen, Punnett, Angela, Horton, Terzah M., Dave, Hema Kishore, Cho, Steve Y., Wu, Yue, Henderson, Tara O., Hoppe, Bradford, Keller, Frank G., Kelly, Kara

Volltext